Table 1 FDA-approved, CAR T-mediated therapies for hematological cancer
From: CAR T cells: engineered immune cells to treat brain cancers and beyond
S No | Trade Names | Proper Names | Route of administration | Indicated diseases | Years of approval |
|---|---|---|---|---|---|
1 | KYMRIAH | Tisagenlecleucel | Intravenous infusion | Lymphoma | 2017 |
2 | YESCARTA | Axicabtagene ciloleucel | Intravenous infusion | Lymphoma | 2017 |
3 | TECARTUS | Brexucabtagene autoleucel | Intravenous infusion | Lymphoma, acute lymphoblastic leukemia | 2020 |
4 | ABECMA | Idecabtagene vicleucel | Intravenous infusion | Multiple myeloma | 2021 |
5 | BREYANZI | Lisocabtagene maraleucel | Intravenous infusion | B cell lymphoma, follicular lymphoma | 2021 |
6 | CARVYKTI | Ciltacabtagene autoleucel | Intravenous infusion | Multiple myeloma | 2022 |